SCPH Earnings

SCPH reported its FY2025Q2 earnings on 2025-08-07, showcasing a revenue of 16.04M against an estimate of 15.41M, resulting in a 4.07% surprise. The EPS was -0.34, surpassing the expected -0.3 by -13.33% . The stock experienced a -7.58% price change on the earnings day and a -4.59% change over the next five days, reflecting market reactions to the results.

Following SCPH's FY2025Q2 earnings announcement on 2025-08-07, the stock price moved by -7.58% on the day of the release. Over the subsequent five days, it saw a -4.59% change. Historically, SCPH's stock price tends to shift by an average of +5.93% in the 10 days leading up to earnings and +4.49% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate SCPH’s annual revenue to reach 19.91M, while the EPS is projected at -0.23. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between SCPH's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SCPH's stock price typically moves by +5.93% in the 10 days before its earnings and +4.49% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of -0.23 and revenue of 19.91M.

The earnings call presents strong financial performance with significant revenue and dose growth, especially in CKD. Despite high COGS and competitive pressures, the anticipated auto-injector launch is expected to improve margins. The Medicare redesign has shifted from a headwind to a tailwind, and the IDN strategy shows promising growth. While cash reserves decreased, management has access to additional funds if needed. Overall, the positive outlook for FUROSCIX, increased prescriptions, and strategic expansions suggest a positive stock price movement.